[Previous Months][Date Index][Thread Index][Join - Register][Login]
  [Message Prev][Message Next][Thread Prev][Thread Next]

[IP] The Benefits of Metformin Therapy During CSII Treatment of Type 1 Patients

Diabetes Care 2002 Dec;25(12):2153-2158 <A
t=pubmed_pubmed&from_uid=12453953">Related Articles,</A> >Links</A>
The Benefits of Metformin Therapy During Continuous Subcutaneous Insulin
Infusion Treatment of Type 1 Diabetic Patients.

Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B.

Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition,
CIC-INSERM, Hopital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy,
Toul, France. Faculty of Medicine, University of Melbourne, Melbourne,
Australia. Faculty of Economics, University of Mons, Mons, Belgium. LIPHA
Sante, Nogent-sur-Marne, France.

OBJECTIVE-This study was designed to assess the insulin-sparing effect of
oral administration of metformin along with a continuous subcutaneous insulin
infusion (CSII) for the treatment of type 1 diabetic patients. RESEARCH
DESIGN AND METHODS-A total of 62 patients (25 women and 37 men) were studied
in a monocenter, randomized, double-blind placebo-controlled study, comparing
metformin (850 mg b.i.d.) with placebo in association with CSII during a
6-month period. RESULTS-Treatment with metformin was associated with a
reduction in daily insulin requirements between V0 and V6 of -4.3 +/- 9.9
units (-7.8 +/- 18%) compared with an increase with placebo treatment of 1.7
+/- 8.3 units (2.8 +/- 12.7%) (P = 0.0043). A decrease in basal requirement
of insulin was also observed in patients treated with metformin of -2.6 +/-
3.2 units (-7.9 +/- 23.8%) compared with an increase with placebo treatment
of 1.9 +/- 5.7 units (8.8 +/- 27.1%) (P = 0.023). HbA(1c) remained unchanged
in treatment with metformin and placebo between V0 and V6. The number of
hypoglycemic events (<60 mg/dl) was similar in both groups. Significant
reductions of total cholesterol (P = 0.04) and LDL cholesterol (P = 0.05)
were observed in patients treated with metformin. Gastrointestinal events,
including diarrhea and abdominal pain, were reported in three patients in the
metformin group who discontinued the trial. Mild or moderate gastrointestinal
side effects were also reported in eight patients treated with metformin and
two patients treated with placebo (P = 0.069). CONCLUSIONS-Metformin was
found to be a safe insulin-sparing agent, when used in combination with CSII
for the treatment of type 1 diabetes.

PMID: 12453953 [PubMed - as supplied by publisher]
for HELP or to subscribe/unsubscribe, contact: